Everolimus-Eluting Stent Proves Signifcantly Safer, More Effective Than Paclitaxel-Eluting Stent In Patients With Coronary Artery Disease
Latebreaking data from SPIRIT IV, a largescale multicenter study of nearly 4,000 patients in the U.S., shows that an everolimuseluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxeleluting stent, and showed that “low late loss” may be achieved with drugeluting stents [...]